Business/Finance In Brief
This article was originally published in The Tan Sheet
Executive Summary
Twinlab: Discontinuation of ephedra sales accounted for 17.1% drop in Q1 revenue to $37.7 mil., Twinlab says in May 15 1earnings release. Hauppauge, N.Y.-based firm recorded net loss of $3.7 mil. in first quarter, compared to net income of $3.7 mil. in Q1 2002. Loss includes "restructuring charges of $1 mil. relating to the facilities consolidation and a gain on the sale of the assets of Bronson Labs" of $800,000. Firm points out net income in Q1 2002 included federal income tax benefit of $6.9 mil. Twinlab has classified its mortgage agreement for Utah facility, borrowings under revolving credit facility as "current liabilities" and is working to amend mortgage agreement, find alternatives to RCF...
You may also be interested in...
Mannatech
Founder and Chairman Sam Caster unanimously appointed CEO by the Board of Directors April 15. He succeeds CEO and Board Member Robert Henry, who will continue to work with the firm as a consultant during the transition...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands